Immuneering to Discuss Pancreatic Cancer Survival Data
Updated overall survival and safety data from a 34‑patient, first‑line pancreatic cancer cohort treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel...
Jon Napitupulu
Groundbreaking Data: Revita Maintains Weight Loss Post-GLP-1
In a randomized, double-blind, sham-controlled midpoint cohort of REMAIN-1 (N=45), Revita produced an additional 2.5% total body weight loss...
Organogenesis Gives Update on Second Phase 3 Renu® Study
ReNu’s second Phase 3 randomized trial in symptomatic knee osteoarthritis missed its primary endpoint, showing a 0.5-point advantage over...
Cidara Doses Patients in Phase 3 Flu Prevention Trial
Cidara has begun dosing in ANCHOR, a global Phase 3 trial of CD388, a single 450 mg subcutaneous dose...
AbbVie’s Rinvoq: A Surging New Option for GCA Treatment
Forty percent of rheumatologists report initiating Rinvoq (upadacitinib) for giant cell arteritis (GCA) within weeks of approval, with nearly...
First Fully Robotic GI Procedure by a Gastroenterologist
In the PARADIGM pivotal IDE trial, a gastroenterologist completed the first fully robotic endoscopic submucosal dissection using EndoQuest’s Endoluminal...
RenovoRx Panther Study Progresses with First Clinical Procedure
RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont...
New Data: CNM-Au8 Improves Brain Energy Metabolism in MS
Topline data: In the combined Phase 2 REPAIR program, 12 weeks of CNM-Au8 increased the brain NAD+/NADH ratio by...
Sparrow’s Remarkable $95M To Advance Diabetes Treatment
Sparrow Pharmaceuticals raised $95 million in a Series B co-led by RA Capital Management and Forbion to advance clofutriben,...
Varmx Receives Key Phase 1 Waiver from Japan’s PMDA
Japan’s PMDA has waived the requirement for a domestic Phase 1 (ethnic bridging) study for VarmX’s VMX-C001, clearing the...